News | December 29, 2025
CPHI & PMEC India 2025 ignites pharma innovation and partnerships
For 2026 onwards, CPHI and PMEC India are evolving into two distinct, specialized shows
For 2026 onwards, CPHI and PMEC India are evolving into two distinct, specialized shows
The collaboration aims to combine synthetic biology with cutting-edge detection technology to create a first-of-its-kind oral pill embedded with tumor-targeting sensors
Wayrilz represents a new approach to ITP by targeting the disease at its root through multi-immune modulation
Emcure becomes the first Indian company to exclusively distribute and commercialise Poviztra, a second brand of Novo Nordisk’s Semaglutide injection for weight management
The randomized, double-blind, placebo-controlled single ascending dose (SAD) study evaluated safety, tolerability, pharmacokinetics, and target engagement in 46 healthy participants
This partnership strengthens LMS as a leading CDMO supplier of peptide materials for both innovator and generic markets
India's pharmaceutical sector is rapidly shifting from a generics-led foundation to an innovation-driven ecosystem
Centanafadine is a first-in-class norepinephrine, dopamine, and serotonin reuptake inhibitor
The new Bioprocess Design Center will serve as a cutting-edge scale-up hub for biologics and vaccine manufacturing
The collaboration to develop breakthrough myeloid cell engagers (MCEs) signals a bold push into a promising new frontier in cancer therapy
Subscribe To Our Newsletter & Stay Updated
_256_275.jpeg)
